Press Release Archive

11.16.2023

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

10.13.2023

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

10.12.2023

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

06.23.2023

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

06.20.2023

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

04.29.2023

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

04.04.2023

FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI

03.16.2023

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

03.16.2023

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™

03.10.2023

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

02.22.2023

Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

02.16.2023

Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study